<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528797</url>
  </required_header>
  <id_info>
    <org_study_id>HR 17718</org_study_id>
    <nct_id>NCT04528797</nct_id>
  </id_info>
  <brief_title>Thyroid and Adrenocortical Hormone Replacement in Organ Donors</brief_title>
  <official_title>Cadaveric Organ Donor Management: Thyroid and Adrenocortical Hormone Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>We Are Sharing Hope SC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain death inevitably leads to hemodynamic instability and prolonged hypotension that&#xD;
      compromises viability of potentially transplantable organs. In addition to depletion of&#xD;
      peripheral norepinephrine stores, concomitant depletion of thyroid hormone and cortisol&#xD;
      levels are believed to contribute to this instability. Catecholamine vasopressors are widely&#xD;
      used to support hemodynamics in potential organ donors, however their use has also been shown&#xD;
      to compromise allograft function.&#xD;
&#xD;
      Trials studying the effects of thyroid hormone and corticosteroid treatment on brain dead&#xD;
      organ donors have had mixed results with respect to improving donor hemodynamics. Further,&#xD;
      few studies have attempted to discriminate the relative contribution of thyroid hormone vs.&#xD;
      corticosteroids.&#xD;
&#xD;
      The specific aims of this study include:&#xD;
&#xD;
        1. To quantify hemodynamic changes during the management of cadaveric organ donors&#xD;
           routinely receiving thyroid hormone therapy alone vs. corticosteroid therapy alone vs.&#xD;
           the combination, compared to those who do not receive any hormonal therapy (controls)&#xD;
&#xD;
        2. To document number and types of organs procured in donors treated with thyroid hormone&#xD;
           therapy alone vs. corticosteroid therapy alone vs. the combination, compared to those&#xD;
           not treated with hormonal therapy (controls)&#xD;
&#xD;
        3. To quantify graft and patient outcomes in recipients of organs exposed to thyroid&#xD;
           hormone therapy alone vs. corticosteroid therapy alone vs. the combination, compared to&#xD;
           recipients of organs not exposed to hormonal therapy (controls).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2010</start_date>
  <completion_date type="Actual">September 30, 2013</completion_date>
  <primary_completion_date type="Actual">August 9, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Vasoactive Inotrope Score (VIS) score from beginning of active donor management until procurement.</measure>
    <time_frame>From baseline (t0) = beginning of active donor management to procurement (tOR) = time of organ procurement, up to 50 hours</time_frame>
    <description>The VIS score includes all commonly used vasopressor and inotrope agents, weighted by potency and summed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of organs procured vs. consented, stratified by treatment group</measure>
    <time_frame>assessed at time of procurement, up to 50 hours following consent for donation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient Morbidity</measure>
    <time_frame>90 days post transplant</time_frame>
    <description>Selected graft recipient morbidity measures in all organs transplanted stratified by treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient Mortality</measure>
    <time_frame>90 days post traansplant</time_frame>
    <description>Recipient death by 90 days post transplant</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Brain Death</condition>
  <arm_group>
    <arm_group_label>Levothyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednsiolone 30 mg/kg (up to 2 g) IV initiated at the beginning of active donor management followed by repeat dosing of 15 mg/kg (up to 1 g) 12 hours later plus levothyroxine 20 mcg IV bolus initiated at the beginning of active donor management followed by continuous infusion of 50 to 200 mcg/hr titrated to minimize vasopressor requirements until organ procurement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No levothyroxine or methylprednisolone administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_label>Levothyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <arm_group_label>Combination</arm_group_label>
    <arm_group_label>Methylprednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cadaveric organ donors â‰¥ age 18 having valid consent (by advance directive or by familial&#xD;
        consent) to donate organs.&#xD;
&#xD;
        Recipients of these cadaveric organs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cadavers failing to meet inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Adrian Van Bakel</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is currently no plan in place to share IPD for this study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

